Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood‐based biomarkers
Abstract
There is an urgent need to identify biomarkers that can accurately detect and diagnose Alzheimer's disease (AD). Autoantibodies are abundant and ubiquitous in human sera and have been previously demonstrated as disease‐specific biomarkers capable of accurately diagnosing mild‐moderate stages of AD and Parkinson's disease.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2016
- Source ID
- 10.1016/j.dadm.2016.03.002
Entities
People
- Abhirup Sarkar
- Benjamin Belinka
- Cassandra A. Demarshall
- Eric L. Goldwaser
- Eric P. Nagele
- George Godsey
- Mary Kosciuk
- Min Han
- Nimish K. Acharya
- Robert G. Nagele
- The Alzheimer’s Disease Neuroimaging Initiative*
- Umashanger Thayasivam
Organizations
- AbbVie
- BioClinica
- Biogen
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Norman Cousins Center for Psychoneuroimmunology
- Pfizer
- Roche (United States)
- Rowan University
- Takeda Pharmaceutical Company
- UMDNJ – School of Osteopathic Medicine
- United States Department of Defense